社区老年人中可干预药物基因组基因型频率、警示药物使用与多重用药的流行率
本研究基于ASPREE试验中13,670名65岁及以上社区老年人,检测10个有可干预药物基因组处方指南的基因,并逐年收集用药数据。结果发现98.8%的参与者携带至少一个可干预基因型,平均每人三个;27.5%使用至少一种指南建议偏离标准处方的药物,83.9%存在多重用药,68.2%使用CYP酶抑制剂或诱导剂。
要点
- 98.8%的社区老年人携带至少一个可干预药物基因组基因型,平均每人三个。
- 27.5%的参与者使用至少一种药物基因组指南建议偏离标准处方的药物。
- 83.9%存在多重用药,68.2%使用CYP酶抑制剂或诱导剂,提示药物相互作用风险。
核心结论
- 社区老年人中可干预药物基因组基因型、多重用药及CYP酶抑制剂/诱导剂使用均高度流行,可能影响处方安全性与有效性。
研究设计与样本
- 基于ASPREE试验的13,670名65岁及以上社区老年人的队列分析,检测10个有可干预处方指南的药物基因组,并每年收集用药数据。
主要发现
- 98.8%的参与者携带至少一个可干预药物基因组基因型,平均每人三个可干预基因型。
- VKORC1(61.1%)和CYP2C19(59.6%)是最常见的可干预基因。
- 他汀类(29.3%)、非甾体抗炎药(14.2%)和质子泵抑制剂(7.9%)是最常用的警示药物。
- 27.5%的参与者使用至少一种药物基因组指南建议偏离标准处方的药物。
- 83.9%的参与者报告多重用药(同时使用≥5种药物),68.2%报告使用至少一种CYP酶抑制剂或诱导剂。
临床怎么用
- 在社区老年人中应关注可干预药物基因组基因型的检测,尤其是VKORC1和CYP2C19。
- 对使用他汀类、非甾体抗炎药和质子泵抑制剂的患者,可结合药物基因组指南调整处方。
- 多重用药及CYP酶抑制剂/诱导剂使用普遍,提示需加强药物相互作用和不良反应监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Older adults (65 years and over) frequently manage complex medication regimens and are vulnerable to adverse drug reactions and treatment inefficacies, some of which could be preventable with pharmacogenetics (PGx)-guided prescribing. This study examined the prevalence of actionable PGx genotypes (i.e., those linked to a guideline that recommends a change to standard prescribing), the use of cautionary medications (i.e., those associated with an actionable PGx genotype), polypharmacy (i.e., ≥ 5 medications simultaneously), and cytochrome P450 enzyme inhibitor and inducer use among 13,670 older adults enrolled in the ASPirin in Reducing Events in the Elderly (ASPREE) trial. Genotyping was conducted for 10 pharmacogenes with actionable PGx-based prescribing guidelines. Medication data were collected annually and assessed to identify cautionary medication use in the cohort. Most participants (98.8%) carried at least one actionable PGx genotype, with an average of three actionable genotypes per participant. VKORC1 (61.1%) and CYP2C19 (59.6%) were the most frequently observed genes with actionable genotypes. Statins (29.3%), nonsteroidal anti-inflammatory drugs (14.2%), and proton-pump inhibitors (7.9%) were the most used cautionary medications, with 27.5% of participants taking at least one medication for which PGx guidelines recommended a deviation from standard prescribing. Most (83.9%) participants reported taking a polypharmacy regimen, and 68.2% reported use of at least one cytochrome P450 enzyme inhibitor or inducer during the trial. Our findings underscore the high prevalence of actionable PGx genotypes, polypharmacy, and use of inhibitors and inducers in older adults, which collectively have the potential to inform safer and more effective prescribing practices.
引用
- Bousman CA, Narang A, Al Bkhetan Z, et al. Prevalence of Actionable Pharmacogenetic Genotype Frequencies, Cautionary Medication Use, and Polypharmacy in Community-Dwelling Older Adults. Clin Pharmacol Ther. 2025. PMID: 40304392. doi:10.1002/cpt.3702
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。